MelaDiff: MR Lymphography and Magnetic Sentinel Lymph Node Biopsy in Melanoma Patients
Study Details
Study Description
Brief Summary
The sentinel lymph nodes (SLNs) are the first lymph nodes (LNs) to drain the tumor site and therefore the first LNs to bare metastases. Hence the importance to investigate these LNs for the best treatment strategy. Current-standard-of-care for melanoma patients with a melanoma stage of pT1b or higher, involve a surgical procedure, referred to as SLN biopsy (SLNB). The SLNB procedure involves a combined detection procedure using a radio-active tracer and blue dye followed by surgical dissection and evaluation of the LNs at the histopathology department. Due to the use of radioisotopes, this procedure suffers from several disadvantages such as limited availability, strict rules and regulations, degradation time in patient and radioactive load for user and patient.
To overcome the limitations of a radioactive tracer, a magnetic SLNB was developed which is facilitated by super paramagnetic iron-oxide (SPIO) nanoparticles. This potentially offers numerous benefits making surgery planning more flexible: no exposure to radiation, easy accessibility of the tracer, long shelf life and long half time in the patient. However, the currently available magnetometer for intraoperative detection of SPIO-enhanced LNs is hampered by a relatively low detection depth, biological noise, and effects of surgical equipment. Therefore, surgeons need to switch to plastic or carbon equipment and the system needs to be balanced prior to each measurement, which increases the surgery time.
A new and effective way to localize SPIOs is differential magnetometry (DiffMag). This patented detection principle, developed by MD&I group at University of Twente (UT), utilizes the nonlinear magnetic response of nanoparticles. An additional advantage of SPIOs is their visibility on MRI, which could provide mapping the SLNs preoperatively. Especially in patients with melanomas on the abdomen or back this would be very useful to see which lymph node stations are connected to the melanoma. In addition, studies have shown that SPIOs are absorbed into lymph nodes in different ways, depending on the presence of metastases. SPIO-enhanced MR lymphography could therefore provide an opportunity for a non-invasive preoperative assessment of nodal status.
In this pilot study the investigators want to evaluate the clinical use of the DiffMag handheld probe. Moreover, the investigators want to map the lymph nodes (metastases) preoperatively using MR lymphography.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: MelaDiff Patients with melanoma of the extremities included in the protocol. Preoperative, patients will receive two MRI-scans and a magnetic tracer injection at the primary tumor site. During surgery, SLNs will be detected using two types of magnetometers (SentiMag® & DiffMag) in combination with Magtrace®, in addition to the standard procedure. |
Device: Magnetic sentinel lymph node biopsy by use of Magtrace®, in combination with SentiMag® and DiffMag
In addition to the standard procedure, SLNs will be detected using two types of magnetometers (SentiMag® & DiffMag) in combination with SPIO particles (Magtrace®).
|
Outcome Measures
Primary Outcome Measures
- True positive/False negative rate for a magnetic SLN detection measured by DiffMag system compared to radioactive detection. [through study completion, an average of 1 year]
Determining the feasibility of SLN detection/localization in melanoma patients using a magnetic tracer (Magtrace®) and hand-held magnetometer DiffMag.
- True positive/False negative rate for a magnetic SLN detection measured by Sentimag system compared to radioactive detection. [through study completion, an average of 1 year]
Determining the feasibility of SLN detection/localization in melanoma patients using a magnetic tracer (Magtrace®) and hand-held magnetometer Sentimag.
Secondary Outcome Measures
- True positive/False negative rate for metastatic SLN using ex vivo MRI [through study completion, an average of 1 year]
Determining the feasibility of LN mapping with preoperative SPIO-enhanced MR lymphography and examining the use of SPIO-enhanced MR lymphography for LN staging.
- True positive/False negative rate for metastatic SLN using in vivo MRI [through study completion, an average of 1 year]
Determining the feasibility of LN mapping with preoperative SPIO-enhanced MR lymphography and examining the use of SPIO-enhanced MR lymphography for LN staging.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with melanoma of the upper or lower extremities scheduled for SLNB;
-
Willing to & able to write informed consent from the subject prior to participation;
-
Willing to & capable of following study procedures;
-
Is older than 18 years;
-
Speaks and understand the Dutch language
Exclusion Criteria:
-
Intolerance / hypersensitivity to iron or dextran compounds
-
Pregnant or lactating patients;
-
Patients having a pacemaker.
-
Patients non eligible for MRI investigation (pacemakers or other implantable devices in the chest wall and/or lower body, claustrophobic, etc.)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Medisch Spectrum Twente | Enschede | Netherlands | ||
| 2 | Ziekenhuisgroep Twente (ZGT) | Hengelo | Netherlands |
Sponsors and Collaborators
- University of Twente
Investigators
- Study Chair: Lejla Alic, PhD, University of Twente
- Principal Investigator: Anneriet Dassen, PhD, Medisch Spectrum Twente Enschede
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NL79537.100.21